睿知中国医院研究地图
候选清单

正在招募肺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  2. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面
  3. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07206498,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Locally advanced or metastatic NSCLC confirmed by pathology;

    入选标准第 2 条

  3. At least one measurable tumor lesion according to RECIST version 1.1; ● Previous radiotherapy-treated lesions cannot be used as target lesions unless imaging studies show clear progression of the lesions.

    入选标准第 6 条

    Received chemotherapy, radiotherapy, biological therapy, targeted therapy, endocrine therapy, immunotherapy, or other anti-tumor drug treatments within 4 weeks before the first administration of the study drug.

    排除标准第 1 条

  4. Physical Status (ECOG PS) score was 0-1;

    入选标准第 7 条

  5. Human immunodeficiency virus (HIV) (HIV1/2 antibody) positive, syphilis spirochete antibody positive .

    排除标准第 10 条

  6. Pregnant or lactating women;

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07206498,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. ≥Age 18, gender is not limited;
  2. Locally advanced or metastatic NSCLC confirmed by pathology;
  3. Patients who have been genetically tested to carry EGFR sensitive mutations;
  4. Blood/Tissue samples must be provided for testing;
  5. Must have a minimum life expectancy of >= 3 months;
  6. At least one measurable tumor lesion according to RECIST version 1.1; ● Previous radiotherapy-treated lesions cannot be used as target lesions unless imaging studies show clear progression of the lesions.
  7. Physical Status (ECOG PS) score was 0-1;
  8. Have full organ function;
  9. Eligible patients (male and female) who are fertile must agree to use a reliable contraceptive method ;
  10. Subjects are required to give informed consent to this study before the experiment and sign a written informed consent voluntarily.

排除标准:Exclusion Criteria:

  1. Received chemotherapy, radiotherapy, biological therapy, targeted therapy, endocrine therapy, immunotherapy, or other anti-tumor drug treatments within 4 weeks before the first administration of the study drug.
  2. Have previously received more than two EGFR-TKI inhibitors for part A;
  3. Received major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks before the first administration, or require elective surgery during the trial period.
  4. Used strong CYP3A4 inhibitors or strong CYP3A4 inducers within 7 days before the first use of the study drugs.
  5. Adverse reactions from previous anti-tumor treatments have not recovered to NCI-CTCAE v5.0 grade ≤1 (except for toxicities judged by the researcher to have no safety risks, such as hair loss, grade 2 peripheral neurotoxicity, and stable thyroid function after hormone replacement therapy).
  6. Skin/pressure ulcers, chronic leg ulcers, known active gastric ulcers, or non-healing wounds.
  7. History of severe allergies, or allergies to any active or inactive ingredients of the study drug;
  8. Severe infections requiring intravenous antibiotic infusion or hospitalization at the time of screening; or uncontrollable active infections within 4 weeks before administration;
  9. Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema);
  10. Human immunodeficiency virus (HIV) (HIV1/2 antibody) positive, syphilis spirochete antibody positive .
  11. Patients with interstitial lung disease.
  12. History of severe cardiovascular diseases.
  13. Unable to orally swallow medication, or there is a condition that significantly affects gastrointestinal absorption as judged by the researcher; Clinical intervention is required for pleural effusion, ascites (excluding subjects who do not need drainage and have been stable for more than 2 weeks after drainage).
  14. Known alcohol or drug dependence.
  15. Mental disorders or poor compliance;
  16. Pregnant or lactating women;
  17. The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study.

引自 ClinicalTrials.gov, NCT07206498, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07206498,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07206498